Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06329882

Doxycycline in Type II Diabetes

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease characterized by hyperglycemia, weight loss, and cardio-metabolic complications. T2DM develops due to the progression of insulin resistance (IR), impairment of insulin insensitivity, and failure of the pancreatic β-cells to release sufficient amount of insulin in response to glucose burden

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Diabetes Mellitus, Type 2 Diabetes Mellitus Endocrine System Diseases Glucose Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

40 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Tanta Unuversity

Tanta, 31527, Egypt

Location status: Recruiting

Location contact

Eman I Elberri, PhD

CONTACT

[email protected]

0201003592593

Mostafa M Bahaa, PhD

SUB_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female sex more than 40 years old Newly diagnosed type II diabetes. HbA1c more than 6.5

Exclusion criteria

  • Patient with chronic kidney disease, hepatic disorders, mental and psychiatric disorders, pregnancy, and lactation

Treatment and study plan

Sitagliptin 100mg

Drug

Sitagliptin is used along with diet and exercise and sometimes with other medications to lower blood sugar levels in adults with type 2 diabetes

Doxycyclin

Drug

Doxycycline belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth.

Primary outcomes

  1. Change in glycemic profile

    Time frame: 3 months

    measurement of fasting blood glucose (FBG)

  2. Change in glycemic profile

    Time frame: 3 months

    measurement of glycated hemoglobin

Sponsors and collaborators

Lead sponsor

Mostafa Bahaa

Other

Registry information

Official study title

Doxycycline in Combination With Sitagliptin on the Glycemic and Cardiac Indices in Patients With Type 2 Diabetes Mellitus

Important dates

Study start
2024
Primary completion
2026
Study completion
2026
First posted
Mar 26, 2024
Registry last updated
Apr 4, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.